KU135, a novel novobiocin-derived c-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells

Molecular Pharmacology

Volumn 76, Issue 6, 2009, Pages 1314-1322

  Shelton, Shary N ^a   Shawgo, Mary E ^a   Matthews, Shawna B ^a   Lu, Yuanming ^b   Donnelly, Alison C ^b   Szabla, Kristen ^d   Tanol, Mehmet ^b   Vielhauer, George A ^a,c   Rajewski, Roger A ^b,c   Matts, Robert L ^d   Blagg, Brian S J ^b,c   Robertson, John D ^a,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3',6 DIMETHOXYBIPHENYL 3 YLCARBOXAMIDO) 6 METHOXY 8 METHYL 2 OXO 2H CHROMEN 7 YL ACETIC ACID; ACETIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ETOPOSIDE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; KU 135; NOVOBIOCIN; PROTEIN BCL 2; PROTEIN BCL XL; TANESPIMYCIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHROMATOGRAPHY, AFFINITY; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; JURKAT CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NOVOBIOCIN; SURFACE PLASMON RESONANCE;

EID: 73149102557     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.058545     Document Type: Article

References (43)

1. Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, and Blagg BS (2006a) High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett 16: 3005-3008.
2. Avila C, Kornilayev BA, and Blagg BS (2006b) Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorg Med Chem 14:1134-1142.
3. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, et al. (2005a) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161.
4. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, and Workman P (2005b) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11: 7023-7032.
5. Blagg BS and Kerr TD (2006) Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 26:310-338.
6. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, and Blagg BS (2008) Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 73:2130-2137.
7. Burlison JA, Neckers L, Smith AB, Maxwell A, and Blagg BS (2006) Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc 128:15529-15536.
8. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, and Neckers L (2003) 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2:123-129.
9. Denault JB, Eckelman BP, Shin H, Pop C, and Salvesen GS (2007) Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. Biochem J 405:11-19.
10. Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, and Blagg BS (2008) The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem 73:8901-8920.
11. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, and Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385-2396.
12. Franklin EE and Robertson JD (2007) Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stressinduced apoptosis. Biochem J 405:115-122.
13. Georgakis GV and Younes A (2005) Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 1:273-281.
14. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, et al. (2005) Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087.
15. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, et al. (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850.
16. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
17. Hartson SD, Thulasiraman V, Huang W, Whitesell L, and Matts RL (1999) Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. Biochemistry 38:3837-3849.
18. Isaacs JS, Xu W, and Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213-217.
19. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, and Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579-5588.
20. Le Bras G, Radanyi C, Peyrat JF, Brion JD, Alami M, Marsaud V, Stella B, and Renoir JM (2007) New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J Med Chem 50: 6189-6200.
21. Li H, Zhu H, Xu CJ, and Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501.
22. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, and Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489.
23. Luo X, Budihardjo I, Zou H, Slaughter C, and Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490.
24. Marcu MG, Chadli A, Bouhouche I, Catelli M, and Neckers LM (2000a) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181-37186.
25. Marcu MG, Schulte TW, and Neckers L (2000b) Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 92:242-248.
26. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, and Erlichman C (2006) A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087-6093.
27. Owen BA, Sullivan WP, Felts SJ, and Toft DO (2002) Regulation of heat shock protein 90 ATPase activity by sequences in the carboxyl terminus. J Biol Chem 277:7086-7091.
28. Powers MV and Workman P (2007) Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581:3758-3769.
29. Radanyi C, Le Bras G, Marsaud V, Peyrat JF, Messaoudi S, Catelli MG, Brion JD, Alami M, and Renoir JM (2009) Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett 274:88-94.
30. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, and Grant S (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63:8420-8427.
31. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, and Orrenius S (2002) Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 277:29803-29809.
32. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, and Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260-266.
33. Schmitt E, Gehrmann M, Brunet M, Multhoff G, and Garrido C (2007) Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81:15-27.
34. Schulte TW, Blagosklonny MV, Ingui C, and Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-24588.
35. Shawgo ME, Shelton SN, and Robertson JD (2008) Caspase-mediated Bak activation and cytochrome c release during intrinsic apoptotic cell death in Jurkat cells. J Biol Chem 283:35532-35538.
36. Shelton SN, Shawgo ME, and Robertson JD (2009) Cleavage of Bid by executioner caspases mediates feed forward amplification of mitochondrial outer membrane permeabilization during genotoxic stress-induced apoptosis in Jurkat cells. J Biol Chem 284:11247-11255.
37. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, et al. (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775-1782.
38. Solit DB and Rosen N (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6:1205-1214.
39. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, and Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1:949-957.
40. Whitesell L, Bagatell R, and Falsey R (2003) The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 3:349-358.
41. Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
42. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, and Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324-8328.
43. Yun BG, Huang W, Leach N, Hartson SD, and Matts RL (2004) Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 43:8217-8229.